Herantis Pharma publishes 2H and FY 2023 report today. - TradingView

HRTIS Stock  EUR 1.49  0.07  4.49%   
Under 61% of Herantis Pharma's investor base is looking to short. The analysis of current outlook of investing in Herantis Pharma Oyj suggests that many traders are alarmed regarding Herantis Pharma's prospects. Herantis Pharma's investing sentiment shows overall attitude of investors towards Herantis Pharma Oyj.
  
Herantis Pharma publishes 2H and FY 2023 report today. TradingView

Read at news.google.com
Google News at Macroaxis
  

Herantis Pharma Fundamental Analysis

We analyze Herantis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Herantis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Herantis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

Herantis Pharma is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Herantis Pharma Oyj Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Herantis Pharma stock to make a market-neutral strategy. Peer analysis of Herantis Pharma could also be used in its relative valuation, which is a method of valuing Herantis Pharma by comparing valuation metrics with similar companies.

Complementary Tools for Herantis Stock analysis

When running Herantis Pharma's price analysis, check to measure Herantis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Herantis Pharma is operating at the current time. Most of Herantis Pharma's value examination focuses on studying past and present price action to predict the probability of Herantis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Herantis Pharma's price. Additionally, you may evaluate how the addition of Herantis Pharma to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
FinTech Suite
Use AI to screen and filter profitable investment opportunities